Site Search
Professionals 672 results
Capabilities 89 results
Region
Winston’s deep experience representing companies and investors across Latin America and the Caribbean has made the firm a “go-to” resource for the strategic development of our clients’ businesses and the vigorous protection of their interests in the region. With broad command of a diverse range of issues within the region’s key industry sectors, we advise Fortune 500 companies, government and quasi-governmental entities, financial institutions, private equity and other investors, domestic and international oil and gas exploration and production companies, refiners and shippers, and a range of commercial and infrastructure developers.
Industry
Insurance plays an essential role in risk mitigation for financial services companies. As risks evolve, questions often arise concerning the scope of insurance coverage and the interpretation and application of policy provisions. Winston’s insurance lawyers provide companies with best-in-class advice, corporate and transactional counsel, and, if need be, litigation defense in high-stakes coverage disputes and class actions. We have achieved excellent outcomes for our clients in matters involving a wide variety of insurance policies and claims, including cybersecurity, travel, long-term care, and annuities, among others. Moreover, we have experience in emerging issues and industries, such as blockchain technology and artificial intelligence, both of which present insurers with a unique and complicated set of risks and opportunities.
Industry
Winston is well regarded for deep and broad experience advising clients in the development, construction, financing and refinancing, acquisition, and operation of major infrastructure assets, including several award-winning deals and public-private-partnership (PPPs or P3s) projects in North America, Latin America, and Europe. Recognized for our ability to “take complex issues and boil them down to pragmatic solutions” (Chambers USA 2023), our team represents a diverse mix of participants and stakeholders in a broad range of investments and non-recourse/limited recourse financings, and we have experience working on many of the most complex projects, within aggressive time frames, while employing inventive solutions. Likewise, our lawyers help to identify and quantify roadblocks and risks at an early stage, so that we can help our clients—which include developers and sponsors, a full range of lenders and investors, project owners and operators, governments and their agencies, and other project counterparties—evaluate and, to the extent possible, mitigate or eliminate risk.
Experience 448 results
Experience
|October 10, 2025
Winston Advises Vistria Affiliate in $136M IPO of Phoenix Education Partners
A Winston & Strawn LLP team led by partners Keerthika Subramanian, Steve Gavin and Timothy Kincaid and including Jacob Tabman, Jeremy Spankowski and Jenna Smith advised TVG-I-E-AEG Holdings, LP, an affiliate of The Vistria Group, as one of the selling stockholders in the $136 million initial public offering of Phoenix Education Partners, Inc. (NYSE: PXED), the parent company of The University of Phoenix, Inc. The IPO valued Phoenix Education Partners, Inc. at approximately $1.35 billion. The transaction marks The University of Phoenix’s return to public markets after nearly a decade as a private company.
Experience
|September 29, 2025
Winston Advises PJT Partners in Beyond Meat’s $1.105 Billion Exchange Offer
Winston & Strawn LLP represented PJT Partners in its role as dealer manager to Beyond Meat, Inc., a publicly traded food technology company and leading producer of plant-based meat alternatives, in connection with an exchange offer and consent solicitation for any and all of its $1.105 billion of 0% Convertible Senior Notes due 2027 for up to $202.5 million in new 7.00% Convertible Senior Secured Second Lien PIK Toggle Notes due 2030 and up to approximately 326 million shares of common stock.
Experience
|September 22, 2025
Winston Paris advised the founders and shareholders of Bylaw, on its acquisition by Septeo
Founded in 2019 by Adrien Aboudaram and Tuan Ardouin, Bylaw has developed next-generation AI technology to automate the processing of legal and financial documents. With a team primarily dedicated to R&D, the legaltech company aims to become the leading AI reference for regulated professions.
Insights & News 7,864 results
Seminar/CLE
|January 22, 2026
14th ITA-IEL-ICC Joint Conference on International Energy Arbitration – Houston
Imad Khan is a proud Co-Chair of The Institute for Transnational Arbitration (ITA), Institute for Energy Law (IEL) and International Chamber of Commerce (ICC) International Court of Arbitration 14th edition of what has become the premier conference on international arbitration in the energy sector. Speakers from around the globe and across the industry will gather to focus on the key issues in the field today.
Sponsorship
|November 20, 2025
Winston & Strawn Sponsors 2025 Smart Business Dealmakers South Florida M&A Conference
Winston & Strawn is proud to sponsor the upcoming Smart Business Dealmakers South Florida M&A Conference. The conference brings together hundreds of local dealmakers, including middle-market CEOs, top investors and lenders, and leading M&A advisers.
Seminar/CLE
|November 13, 2025
AI in Action: Legal Strategies for Healthcare Innovation
We are bringing together stakeholders across the healthcare ecosystem—from front-line providers to financial backers—for a panel discussion on AI in healthcare.
Other Results 79 results
Law Glossary
What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?
Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in 2010 an amendment of the Public Health Services Act. The BPCIA is codified at 42 U.S.C. § 262.
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)